{
  "documentMetadata": {
    "title": "Syphilis, CNS",
    "sourceFile": "syndromes/genitourinary/syphilis/Syphilis, CNS.pdf",
    "lastUpdated": "2024-07-01"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Clinical evidence of neurologic involvement with syphilis:",
        "  Cognitive dysfunction",
        "  Motor or sensory deficits",
        "  Ophthalmic or auditory symptoms: ANY eye or ear involvement is considered neurosyphilis, and should be treated as such even if LP is normal!",
        "  Cranial nerve palsies",
        "  Symptoms or signs of meningitis",
        "Diagnosis: cannot depend on screen with RPR/VDRL as 25% can spontaneously becomes negative after 5 years or more. Screen with FTA-ABS. (Ann Int Med 104:368,1986)",
        "Patients with these symptoms or presentation need a CSF exam unless isolated ocular or otic symptoms.",
        "If isolated ocular signs and symptoms with reactive serological studies, diagnostic CSF not required (about 40% ocular will have normal CSF) though would consider exam when symptoms present with normal exam.",
        "If isolated otic signs and symptoms with reactive serological studies, diagnostic CSF not required (about 90% will have normal CSF)",
        "CSF VDRL very specific but not sensitive. If suggestive clinical picture, negative CSF VDRL, but presence of > 20 WBCs, treat as neurosyphilis: Sex Trans Dis 39:291, 2012."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Treponema pallidum"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Penicillin G",
            "dose": "3-4 million units",
            "route": "IV",
            "frequency": "q4h"
          }
        ],
        "durationDetail": {
          "fixedDuration": "10-14 days"
        }
      }
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Procaine Penicillin G",
            "dose": "2.4 million units",
            "route": "IM",
            "frequency": "q24h",
            "connector": "+"
          },
          {
            "drug": "Probenecid",
            "dose": "0.5 gm",
            "route": "po",
            "frequency": "qid"
          }
        ],
        "durationDetail": {
          "fixedDuration": "10-14 days"
        },
        "notes": "(Clin Infect Dis 2020;71:267)"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Ceftriaxone",
            "dose": "1-2 gm",
            "route": "IV or IM",
            "frequency": "q24h"
          }
        ],
        "durationDetail": {
          "fixedDuration": "10-14 days"
        },
        "notes": "(Retrospective study in France supportive: Lancet Inf Dis 21:1441, 2021)."
      }
    },
    {
      "type": "paragraph",
      "text": "Ceftriaxone recommended as an alternative in European 2020 Syphilis Guidelines but not 2021 CDC STD Guidelines MMWR Recomm Rep 70:1, 2021"
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "For penicillin allergy: either desensitize the patient to penicillin or obtain infectious diseases consultation. See methods for Parenteral Penicillin Desensitization.",
        "Serologic criteria for response to treatment: 4-fold or greater decrease in VDRL titer over 6-12 months: Clin Infect Dis 2015 61:S818.",
        "Repeat LP not needed if responsive by serological and clinical criteria",
        "Syphilis references, JAMA 312:1905, 2014, Lancet Infect Dis 4:456, 2004; Lancet 2017 389:1550.",
        "See 2021 CDC STD Guidelines MMWR Recomm Rep 70:1, 2021 or European 2020 Syphilis Guidelines",
        "Review of evidence for CDC guidelines: Clin Infect Dis 74:S127 2022",
        "General references on neurosyphilis: N Engl J Med 2019;381:1358; Clin. Infect. Dis. 2024;78:1085"
      ]
    }
  ]
}
